Akari Therapeutics (NASDAQ:AKTX) Upgraded by Maxim Group to Buy Rating

Maxim Group upgraded shares of Akari Therapeutics (NASDAQ:AKTX) from a hold rating to a buy rating in a report issued on Monday morning, Marketbeat reports. The brokerage currently has $30.00 target price on the biopharmaceutical company’s stock.

Several other research firms have also recently issued reports on AKTX. Wall Street Zen upgraded shares of Akari Therapeutics to a “sell” rating in a research note on Saturday, June 27th. HC Wainwright lifted their price target on shares of Akari Therapeutics to $27.00 and gave the stock a “buy” rating in a research note on Wednesday, April 1st. Finally, Weiss Ratings raised shares of Akari Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Akari Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $32.33.

Akari Therapeutics Stock Down 3.2%

Akari Therapeutics stock opened at $10.66 on Monday. Akari Therapeutics has a one year low of $3.02 and a one year high of $49.60. The business’s fifty day moving average is $11.79 and its 200 day moving average is $9.44.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Akari Therapeutics stock. Armistice Capital LLC bought a new position in Akari Therapeutics PLC (NASDAQ:AKTX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned about 5.95% of Akari Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 5.06% of the stock is owned by institutional investors and hedge funds.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.